Combining orally available selective estrogen receptor degraders with pan-HER tyrosine kinase inhibitor neratinib in pre-clinical models of HER2+/ER+ breast cancer

npj Breast Cancer · Published 2026-08-05 · DOI 10.1038/s41523-026-01012-0

Free full text

Authors (12)

Amira F. Mahdi, Myra Castel, Neil T. Conlon, Debbie O’Reilly, Niall Ashfield, Alexander Caffrey, Ailish Carey, Neil A. O’Brien, Enrique Guandique, Georg F. Bischof, John Crown, Denis M. Collins

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Mahdi, A., Castel, M., Conlon, N., et al. (2026). Combining orally available selective estrogen receptor degraders with pan-HER tyrosine kinase inhibitor neratinib in pre-clinical models of HER2+/ER+ breast cancer. npj Breast Cancer. https://doi.org/10.1038/s41523-026-01012-0

Related articles

• Risk factors and metastatic sites in HER2-positive breast cancer with pathological complete response · npj Breast Cancer · 2026 · Same journal
• Anlotinib-containing regimens in HR+ advanced breast cancer after prior CDK4/6 inhibitor progression · npj Breast Cancer · 2026 · Same journal
• Clinical significance of residual microcalcifications after neoadjuvant chemotherapy: MRI response and the subtypes · npj Breast Cancer · 2026 · Same journal
• Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial · npj Breast Cancer · 2026 · Same journal
• Enabling DCIS subtyping: leveraging foundation models for robust grading and molecular biomarker scoring · npj Breast Cancer · 2026 · Same journal
• Facing death: the last drawings of a woman with breast cancer at the end of life · npj Breast Cancer · 2026 · Same journal
• Impact of neoadjuvant chemotherapy on local breast microbiota and macrophages in ER-positive breast cancer with links to treatment response · npj Breast Cancer · 2026 · Same journal
• PCSK9 rs562556 variant and survival in BRCA1 mutation carriers and mutation-negative familial breast cancer · npj Breast Cancer · 2026 · Same journal
• Patient-reported outcomes as early indicators of recurrence, disease progression, and survival via machine learning in breast cancer · npj Breast Cancer · 2026 · Same journal
• External validation of four breast cancer risk prediction models for personalized screening in a prospective Dutch screening cohort · npj Breast Cancer · 2026 · Same journal